Compugen Ltd. (NASDAQ:CGEN – Get Rating) – SVB Leerink raised their Q2 2022 earnings estimates for Compugen in a research note issued on Tuesday, May 17th. SVB Leerink analyst D. Graybosch now anticipates that the biotechnology company will post earnings per share of ($0.11) for the quarter, up from their prior forecast of ($0.13). SVB Leerink has a “Outperform” rating and a $9.00 price target on the stock. SVB Leerink also issued estimates for Compugen’s Q3 2022 earnings at ($0.11) EPS, Q4 2022 earnings at ($0.15) EPS, FY2022 earnings at ($0.49) EPS, Q1 2023 earnings at ($0.13) EPS, Q2 2023 earnings at ($0.13) EPS, Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.20) EPS, FY2023 earnings at ($0.57) EPS, FY2024 earnings at ($0.98) EPS, FY2025 earnings at ($1.87) EPS and FY2026 earnings at ($1.49) EPS.
Compugen (NASDAQ:CGEN – Get Rating) last posted its earnings results on Monday, May 16th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. During the same quarter in the previous year, the company posted ($0.12) earnings per share.
Shares of CGEN opened at $1.93 on Thursday. Compugen has a 52-week low of $1.66 and a 52-week high of $9.20. The stock’s 50-day simple moving average is $2.73 and its 200 day simple moving average is $3.67.
Hedge funds have recently added to or reduced their stakes in the stock. Bridgefront Capital LLC bought a new stake in Compugen in the third quarter valued at approximately $61,000. Invesco Ltd. bought a new stake in shares of Compugen during the 2nd quarter valued at $92,000. Virtu Financial LLC purchased a new stake in shares of Compugen in the 1st quarter worth about $37,000. Oppenheimer & Co. Inc. purchased a new position in Compugen during the 4th quarter valued at about $49,000. Finally, Walleye Trading LLC bought a new stake in Compugen during the fourth quarter worth about $55,000.
About Compugen (Get Rating)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.